Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer

Chung Wei Fan, Chung Chuan Chan, Kuei Tien Chen, Jen Twu, Ya Shu Huang, Chia Li Han, Yu Ju Chen, Jau Song Yu, Yu Sun Chang, Yung Bin Kuo, Err Cheng Chan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: To identify novel serological biomarkers for human colorectal cancer (CRC), we analyzed CRC tissues using gel-assisted digestion and isobaric tags with related and absolute quantitation (iTRAQ) labeling mass spectrometry (MS). By comparing pairs of tumor tissues and matched normal tissues, we discovered the SEC61β with expression changes 3.3-fold and a marginal statistical significance (p= 0.052) previously. Methods: SEC61β expression in CRC tissues was further analyzed by western blotting and immunohistochemistry. We next assessed the putative diagnostic value of the SEC61β autoantibody as a serum marker. Results: Using western blotting analysis, SEC61β expression was increased 1.9-fold in tumor tissues. Immunohistochemical analysis of 64 CRC specimens showed that SEC61β was positively detected in 64% of the tumors, but weakly or not detected in > 80% of the adjacent nontumor epithelial cells. Western blot analysis with plasma samples showed that the sensitivity and specificity of the SEC61β autoantibody from patients with CRC were 79% and 75%, respectively. Importantly, the results of the SEC61β autoantibody for early detection of colorectal cancer revealed a higher sensitivity of 77% than the carcinoembryonic antigen (CEA) assay. Conclusions: Measurement of SEC61β autoantibody levels may provide an alternative detection indicator for CRC, particularly among early-stage patients.

Original languageEnglish
Pages (from-to)887-893
Number of pages7
JournalClinica Chimica Acta
Volume412
Issue number11-12
DOIs
Publication statusPublished - May 12 2011
Externally publishedYes

Fingerprint

Biomarkers
Autoantibodies
Colorectal Neoplasms
Tissue
Tumors
Carcinoembryonic Antigen
Western Blotting
Far-Western Blotting
Labeling
Neoplasms
Mass spectrometry
Assays
Gels
Early Detection of Cancer
Plasmas
Digestion
Mass Spectrometry
Epithelial Cells
Immunohistochemistry
Sensitivity and Specificity

Keywords

  • Autoantibody
  • Colorectal cancer
  • SEC61β
  • Serological biomarker

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Fan, C. W., Chan, C. C., Chen, K. T., Twu, J., Huang, Y. S., Han, C. L., ... Chan, E. C. (2011). Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer. Clinica Chimica Acta, 412(11-12), 887-893. https://doi.org/10.1016/j.cca.2011.01.012

Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer. / Fan, Chung Wei; Chan, Chung Chuan; Chen, Kuei Tien; Twu, Jen; Huang, Ya Shu; Han, Chia Li; Chen, Yu Ju; Yu, Jau Song; Chang, Yu Sun; Kuo, Yung Bin; Chan, Err Cheng.

In: Clinica Chimica Acta, Vol. 412, No. 11-12, 12.05.2011, p. 887-893.

Research output: Contribution to journalArticle

Fan, CW, Chan, CC, Chen, KT, Twu, J, Huang, YS, Han, CL, Chen, YJ, Yu, JS, Chang, YS, Kuo, YB & Chan, EC 2011, 'Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer', Clinica Chimica Acta, vol. 412, no. 11-12, pp. 887-893. https://doi.org/10.1016/j.cca.2011.01.012
Fan, Chung Wei ; Chan, Chung Chuan ; Chen, Kuei Tien ; Twu, Jen ; Huang, Ya Shu ; Han, Chia Li ; Chen, Yu Ju ; Yu, Jau Song ; Chang, Yu Sun ; Kuo, Yung Bin ; Chan, Err Cheng. / Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 11-12. pp. 887-893.
@article{40d002cbea27478696951219c446379d,
title = "Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer",
abstract = "Background: To identify novel serological biomarkers for human colorectal cancer (CRC), we analyzed CRC tissues using gel-assisted digestion and isobaric tags with related and absolute quantitation (iTRAQ) labeling mass spectrometry (MS). By comparing pairs of tumor tissues and matched normal tissues, we discovered the SEC61β with expression changes 3.3-fold and a marginal statistical significance (p= 0.052) previously. Methods: SEC61β expression in CRC tissues was further analyzed by western blotting and immunohistochemistry. We next assessed the putative diagnostic value of the SEC61β autoantibody as a serum marker. Results: Using western blotting analysis, SEC61β expression was increased 1.9-fold in tumor tissues. Immunohistochemical analysis of 64 CRC specimens showed that SEC61β was positively detected in 64{\%} of the tumors, but weakly or not detected in > 80{\%} of the adjacent nontumor epithelial cells. Western blot analysis with plasma samples showed that the sensitivity and specificity of the SEC61β autoantibody from patients with CRC were 79{\%} and 75{\%}, respectively. Importantly, the results of the SEC61β autoantibody for early detection of colorectal cancer revealed a higher sensitivity of 77{\%} than the carcinoembryonic antigen (CEA) assay. Conclusions: Measurement of SEC61β autoantibody levels may provide an alternative detection indicator for CRC, particularly among early-stage patients.",
keywords = "Autoantibody, Colorectal cancer, SEC61β, Serological biomarker",
author = "Fan, {Chung Wei} and Chan, {Chung Chuan} and Chen, {Kuei Tien} and Jen Twu and Huang, {Ya Shu} and Han, {Chia Li} and Chen, {Yu Ju} and Yu, {Jau Song} and Chang, {Yu Sun} and Kuo, {Yung Bin} and Chan, {Err Cheng}",
year = "2011",
month = "5",
day = "12",
doi = "10.1016/j.cca.2011.01.012",
language = "English",
volume = "412",
pages = "887--893",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "11-12",

}

TY - JOUR

T1 - Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer

AU - Fan, Chung Wei

AU - Chan, Chung Chuan

AU - Chen, Kuei Tien

AU - Twu, Jen

AU - Huang, Ya Shu

AU - Han, Chia Li

AU - Chen, Yu Ju

AU - Yu, Jau Song

AU - Chang, Yu Sun

AU - Kuo, Yung Bin

AU - Chan, Err Cheng

PY - 2011/5/12

Y1 - 2011/5/12

N2 - Background: To identify novel serological biomarkers for human colorectal cancer (CRC), we analyzed CRC tissues using gel-assisted digestion and isobaric tags with related and absolute quantitation (iTRAQ) labeling mass spectrometry (MS). By comparing pairs of tumor tissues and matched normal tissues, we discovered the SEC61β with expression changes 3.3-fold and a marginal statistical significance (p= 0.052) previously. Methods: SEC61β expression in CRC tissues was further analyzed by western blotting and immunohistochemistry. We next assessed the putative diagnostic value of the SEC61β autoantibody as a serum marker. Results: Using western blotting analysis, SEC61β expression was increased 1.9-fold in tumor tissues. Immunohistochemical analysis of 64 CRC specimens showed that SEC61β was positively detected in 64% of the tumors, but weakly or not detected in > 80% of the adjacent nontumor epithelial cells. Western blot analysis with plasma samples showed that the sensitivity and specificity of the SEC61β autoantibody from patients with CRC were 79% and 75%, respectively. Importantly, the results of the SEC61β autoantibody for early detection of colorectal cancer revealed a higher sensitivity of 77% than the carcinoembryonic antigen (CEA) assay. Conclusions: Measurement of SEC61β autoantibody levels may provide an alternative detection indicator for CRC, particularly among early-stage patients.

AB - Background: To identify novel serological biomarkers for human colorectal cancer (CRC), we analyzed CRC tissues using gel-assisted digestion and isobaric tags with related and absolute quantitation (iTRAQ) labeling mass spectrometry (MS). By comparing pairs of tumor tissues and matched normal tissues, we discovered the SEC61β with expression changes 3.3-fold and a marginal statistical significance (p= 0.052) previously. Methods: SEC61β expression in CRC tissues was further analyzed by western blotting and immunohistochemistry. We next assessed the putative diagnostic value of the SEC61β autoantibody as a serum marker. Results: Using western blotting analysis, SEC61β expression was increased 1.9-fold in tumor tissues. Immunohistochemical analysis of 64 CRC specimens showed that SEC61β was positively detected in 64% of the tumors, but weakly or not detected in > 80% of the adjacent nontumor epithelial cells. Western blot analysis with plasma samples showed that the sensitivity and specificity of the SEC61β autoantibody from patients with CRC were 79% and 75%, respectively. Importantly, the results of the SEC61β autoantibody for early detection of colorectal cancer revealed a higher sensitivity of 77% than the carcinoembryonic antigen (CEA) assay. Conclusions: Measurement of SEC61β autoantibody levels may provide an alternative detection indicator for CRC, particularly among early-stage patients.

KW - Autoantibody

KW - Colorectal cancer

KW - SEC61β

KW - Serological biomarker

UR - http://www.scopus.com/inward/record.url?scp=79955049239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955049239&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2011.01.012

DO - 10.1016/j.cca.2011.01.012

M3 - Article

VL - 412

SP - 887

EP - 893

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 11-12

ER -